V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Cerevel Therapeutics Holdings Executive Compensation (FY22)

CERE · Executive and director compensation, fiscal 2022 only

The paid brief on Cerevel Therapeutics Holdings

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 7, 2026Latest filing (DEF 14A): April 28, 2023
1 filing cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Cerevel Therapeutics Holdings brief$1,500Get the executive brief
124 figures on this page, cited to the filing that reported them. See the citations
Chief executive, fiscal 2022
◇
N. Anthony Coles
Chief executive pay ratio
◇
To the median employee

More on Cerevel Therapeutics Holdings

Five data products on this company. Each one is requested through the developer setup page.

Frequently asked questions

Answers drawn from the data on this page.
Who is Cerevel Therapeutics Holdings' chief executive and what were they paid?
N. Anthony Coles was paid $11,225,426 in total compensation as Chief Executive Officer and Chairperson of the Board of Directors for fiscal 2022.
Which companies are in Cerevel Therapeutics Holdings' peer group?
The disclosed peer group includes Alector, Allogene Therapeutics, Arcus Biosciences, Arvinas and Axsome Therapeutics, among others.
What is Cerevel Therapeutics Holdings' chief executive pay ratio?
For fiscal 2022, the company reported a chief executive pay ratio of 35:1.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
N. Anthony Coles
Chief Executive Officer and Chairperson of the Board of Directors
◇——◇◇——◇
Raymond Sanchez
Chief Medical Officer
◇——◇◇—◇◇
John Renger
Chief Scientific Officer
◇——◇◇—◇◇
Abraham Ceesay
President
◇——◇◇—◇◇
Mark Bodenrader
Interim Chief Financial Officer; Senior Vice President, Finance and Chief Accounting Officer
Served on an interim basis
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Abraham CeesayOPTION◇——◇—◇◇
John RengerOPTION◇——◇—◇◇
Mark BodenraderRSU◇——◇——◇
Mark BodenraderOPTION◇——◇—◇◇
N. AnthonyOPTION◇——◇—◇◇
Raymond SanchezOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2022 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Mark BodenraderRSU◇◇——
Option◇—◇2/9/2032
Option◇—◇10/28/2030
Option◇—◇9/23/2029
Option◇—◇2/3/2031
Option◇—◇9/23/2029
N. Anthony ColesOption◇—◇2/9/2032
Option◇—◇2/3/2031
Option◇—◇10/28/2030
Raymond SanchezOption◇—◇2/9/2032
Option◇—◇2/27/2029
Option◇—◇2/3/2031
Option◇—◇10/28/2030
Option◇—◇2/27/2029
John RengerOption◇—◇10/28/2030
Option◇—◇4/2/2029
Option◇—◇2/3/2031
Option◇—◇4/2/2029
Option◇—◇2/9/2032
Abraham CeesayOption◇—◇2/9/2032
Option◇—◇6/1/2031
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2022
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Norbert Riedel, Ph.D
Lead independent director
◇—◇———◇
Gabrielle Sulzberger, J.D., M.B.A
◇—◇———◇
Marijn Dekkers, Ph.D
◇—◇———◇
Christopher Gordon, M.B.A
◇—◇———◇
Doug Giordano, M.B.A
◇—◇———◇
Adam Koppel, M.D., Ph.D
◇—◇———◇
Deval Patrick, J.D
◇—◇———◇
Ruth McKernan, Ph.D., CBE, FMedSci
◇—◇———◇
Suneet Varma, M.B.A, Deborah Baron, M.B.A, N. Anthony Coles, M.D and Morris Birnbaum, M.D., Ph.D served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
  • Alector ALEC
  • Allogene Therapeutics ALLO
  • Arcus Biosciences RCUS
  • Arvinas ARVN
  • Axsome Therapeutics AXSM
  • BridgeBio Pharma BBIO
  • Denali Therapeutics DNLI
  • Fate Therapeutics FATE
  • Intellia Therapeutics NTLA
  • Karuna Therapeutics KRTX
  • Neurocrine Biosciences NBIX
  • Replimune Group REPL
  • Sage Therapeutics SAGE
  • Zymeworks ZYME

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Cerevel Therapeutics Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Cerevel Therapeutics Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Cerevel Therapeutics Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Cerevel Therapeutics Holdings' disclosed peer group is defensible, who names Cerevel Therapeutics Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
124 figures on this page, cited to the filing that reported them.
124 cited to the filing

Documents cited

  1. 0000950170-23-015766
    CEO Pay Ratio · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Outstanding Equity Awards · and 1 more section
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Cerevel Therapeutics Holdings executive compensation, FY2022.” https://intel.velarion.ai/comp/CERE (accessed 2026).
Short form: data: Velarion

The paid brief for Cerevel Therapeutics Holdings

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Cerevel Therapeutics Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Cerevel Therapeutics Holdings discloses

The companies named in CERE's own disclosed peer group.

AlectorAllogene TherapeuticsArcus BiosciencesArvinasAxsome TherapeuticsBridgeBio PharmaDenali TherapeuticsFate TherapeuticsIntellia TherapeuticsKaruna TherapeuticsNeurocrine BiosciencesReplimune GroupSage TherapeuticsZymeworks

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy